Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Neuroendocrine carcinoma
Stage/Subtype:  thyroid gland medullary carcinoma
Country:  U.S.A.
Trial Type:  Treatment
Results 1-5 of 5 for your search:
Start Over
Vaccine Therapy in Treating Patients with Recurrent or Metastatic Medullary Thyroid Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-C-0095, NCI-2013-01587, 1301-1199, GI-6207, GI-6207-02, P11934, RD-13-I-10, NCT01856920
Regorafenib in Treating Patients with Metastatic Medullary Thyroid Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-350, NCI-2016-00333, NCT02657551
Liposomal Irinotecan and Veliparib in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Status: Temporarily closed
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9914, NCI-2015-02125, TBD, NCT02631733
Expanded Access of Cabozantinib in Medullary Thyroid Cancer
Status: Not yet active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: XL184-209, NCI-2012-02141, NCT01683110
Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients with Metastatic Endocrine Cancer
Status: Active
Phase: No phase specified
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 2014-0864, NCI-2015-02058, NCT02592356
Start Over